Partnership follows tie-up with China's 3SBio earlier this year

The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.

Partnership follows tie-up with China's 3SBio earlier this year